Repurposing an Old Drug: Aprotinin Shows In Vitro Anti‑SARS‑CoV‑2 Activity
A study published in Cells brings new insights into the repurposing of old antiviral drugs. Aprotinin (APT), a marketed serine protease inhibitor, is conventionally used to reduce bleeding during surgery. This research reveals that it can effectively block SARS‑CoV‑2 replication in vitro.
To enter host cells, SARS‑CoV‑2 relies on the human protease TMPRSS2 to cleave its spike protein. Aprotinin disrupts this step and prevents viral entry. Notably, α1‑antitrypsin, another protease inhibitor, shows no obvious antiviral effect at the same concentration. The antiviral activity of aprotinin has been validated across multiple cell models and SARS‑CoV‑2 isolates.
The study also notes that SARS‑CoV‑2 infection suppresses endogenous protease inhibitors in cells. Aprotinin compensates for this loss and keeps inhibiting viral replication in subsequent cycles. An inhaled aprotinin aerosol is already approved in Russia. Local respiratory administration may curb viral load in the lungs at early infection stages and reduce progression to severe disease.
Nevertheless, all findings are from in vitro cell tests. Aprotinin interferes with the human coagulation‑fibrinolysis system. Severe COVID‑19 often comes with coagulation disorders, so its safety risks require careful assessment. Industry experts state that aprotinin still needs full animal and clinical trials before it can be used for COVID‑19 treatment.
FOR DETAIL: https://doi.org/10.3390/cells9112377
Article from:
